WEBULL
WebtradeDownload

How BeOne’s Exclusive Asian Rights to RAS(ON) Inhibitors Will Impact BeOne Medicines (ONC) Investors

Simply Wall St · 1d ago
  • Earlier in August 2026, BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a multi-part collaboration that pairs BeOne’s oncology assets with Revolution’s four clinical RAS(ON) inhibitors and grants BeOne exclusive development and commercialization rights to these agents in select Asian markets, alongside BeOne funding a global registrational Phase 3 study.
  • This collaboration meaningfully expands BeOne’s access to late-stage targeted cancer candidates and deepens its role in global trial execution, potentially reshaping its oncology franchise in key Asian territories.
  • We will now examine how BeOne’s newly secured exclusive Asian rights to Revolution’s RAS(ON) inhibitors could influence the company’s investment narrative.

The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

BeOne Medicines Investment Narrative Recap

To own BeOne Medicines, you need to believe it can convert its growing oncology footprint into durable, diversified earnings beyond BRUKINSA and CLL. In the near term, the key catalyst remains execution on late stage oncology trials, while the biggest risk is still heavy product concentration and intensifying competition. The Revolution Medicines collaboration could lessen that concentration over time, but near term it mainly raises execution and trial delivery risk rather than altering the central catalyst.

Among recent announcements, the raised 2026 guidance to US$6.6 billion to US$6.8 billion in revenue and US$1.0 billion to US$1.1 billion in GAAP operating income stands out. It frames how investors might think about the Revolution Medicines deal: BeOne is layering new RAS(ON) assets and a company funded global Phase 3 onto a business already targeting higher profitability, which may heighten sensitivity to any delays, cost overruns, or setbacks in executing this expanded trial agenda.

Yet behind the stronger guidance, investors should be aware that concentrated reliance on BRUKINSA and expanded trial commitments could...

Read the full narrative on BeOne Medicines (it's free!)

BeOne Medicines’ narrative projects $8.5 billion revenue and $1.6 billion earnings by 2029.

Uncover how BeOne Medicines' forecasts yield a $412.35 fair value, a 14% upside to its current price.

Exploring Other Perspectives

ONC 1-Year Stock Price Chart
ONC 1-Year Stock Price Chart

Some of the lowest analysts were already cautious, assuming only about 10 percent annual revenue growth to around US$7.7 billion by 2029 and earnings near US$1.0 billion, so this new RAS(ON) collaboration may either ease their concerns about single drug dependence or deepen worries about higher trial costs and execution risks, which is why you should weigh several viewpoints before deciding what this news means for you.

Explore 5 other fair value estimates on BeOne Medicines - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

Searching For A Fresh Perspective?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

  • Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
  • Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
  • Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.